Efficacy and Safety of Levetiracetam in Pediatric Migraine

Headache

Volumn 44, Issue 3, 2004, Pages 238-243

  Miller, G Steve ^a  

^a Children's Medical Center   (United States)

Author keywords

Antiepileptic drug; Levetiracetam; Pediatric migraine

Indexed keywords

ANTIMIGRAINE AGENT; ETIRACETAM;

ADOLESCENT; ASTHENIA; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSTILITY; HUMAN; HYPERACTIVITY; IRRITABILITY; MALE; MIGRAINE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PIRACETAM; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 1842579037     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04053.x     Document Type: Review

References (41)

1. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized migraine headache in a United States population. Neurology. 1999;53:1468-1473.
2. Linder SL, Winner P. Pediatric headache. Med Clin North Am. 2001;85:1037-1053.
3. Lewis DW, Scott D, Rendin V. Treatment of pediatric headache. Expert Opin Pharmacother. 2002;3:1433-1442.
4. Prensky A. Childhood migraine headache syndromes. Curr Treat Options Neurol. 2001;3:257-270.
5. Wasiewski WW. Preventive therapy in pediatric migraine. J Child Neurol. 2001;16:71-78.
6. Hershey AD, Powers SW, Vockell AL, et al. Effectiveness of topiramate in the prevention of childhood headaches. Headache. 2002;42:810-818.
7. Pakalnis A, Greenberg G, Drake ME Jr, et al. Pediatric migraine prophylaxis with divalproex. J Child Neurol. 2001;16:731-734.
8. Serdarogul G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. Headache. 2002;42:819-822.
9. Troost BT, Wiles RM. Two-phase open-label study of levetiracetam in the management of intractable headache. Paper presented at: Diamond Headache Meeting; January 11-15, 2003; Rancho Mirage, Calif.
10. Drake ME, Greathouse MI, Armentbright AD, Brenner JB. Levetiracetam for preventive treatment of migraine [abstract]. Cephalalgia. 2001;21:373.
11. Kruscz JC. Levetiracetam as prophylaxis for resistant headaches [abstract]. Cephalalgia. 2001;21:373.
12. Turner IM, Entin EJ, Newman SM, Agrillo T. Levetiracetam for migraine prophylaxis. Paper presented at: Diamond Headache Meeting; July 15-19, 2003; Buena Vista, Fla.
13. Lindholm D. Levetiracetam levels correlating with successful treatment of epilepsy, headaches, cognitive effects, and adverse reactions in pediatric age group [abstract]. Epilepsia. 2002;43(suppl 7):60.
14. Keppra [package insert]. Smyrna, Ga: UCB Pharma, Inc; 2003.
15. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000;41:1276-1283.
16. Ben-Menachem E, Edrich P, Van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res. 2003;53:57-64.
17. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80-87.
18. Boon P, Chauvel P, Pohlmann-Eden B, Otoul C, Wroe S. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res. 2002;48:77-89.
19. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-242.
20. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia. 2001;42(suppl 4):31-35.
21. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 2000;41:1179-1186.
22. Ardid D, Lamberty Y, Alloui A, et al. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol. 2003;473:27-33.
23. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10:287-293.
24. Rigo JM, Hans G, Nguyen L, et al. The antiepileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136:659-672.
25. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18.
26. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518-524.
27. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol. 2002;17:413-415.
28. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42:1574-1579.
29. Mintz M, Graner CA, Blumenfeld S, et al. Levetiracetam monotherapy in pediatric patients [abstract]. Epilepsia. 2002;43(suppl 7):62.
30. Frost MD, Gustafson MC, Ritter FJ. Use of levetiracetam (lev) in children under two years of age [abstract]. Epilepsia. 2002;43(suppl 7):57.
31. Maytal J, Young M, Sheckter A, et al. Pediatric migraine and the International Headache Society (IHS) criteria. Neurology. 1997;48:602-607.
32. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16:611-634.
33. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77-85.
34. French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(suppl 4):40-43.
35. Fix A, Sadek AH, Ting T, et al. Safety profile of levetiracetam [abstract]. Epilepsia. 2002;43(suppl 7):206.
36. Depakote [package insert]. North Chicago, Ill: Abbott Laboratories; 2003.
37. Topamax [package insert]. Raritan, NJ: OrthoMcNeil Pharmaceutical, Inc; 2003.
38. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52:321-327.
39. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002;22:27-39.
40. Gates JR, Folland C, Ankenbauer JL, et al. Behavioral side effects of levetiracetam [abstract]. Epilepsia. 2002;43(suppl 7):187.
41. Miller GS. Pyridoxine ameliorates adverse behavioral effects of levetiracetam in children [abstract]. Epilepsia. 2002;43(suppl 7):62.